Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Chendu DIAO Pharmaceutical Group CO., LTD. clinical trials
The registry lists 9 studies whose lead sponsor is Chendu DIAO Pharmaceutical Group CO., LTD. or one of 1 company grouped under it. 5 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Keep track of what changes. Save the Chendu DIAO Pharmaceutical Group CO., LTD. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Chendu DIAO Pharmaceutical Group CO., LTD..
- Chendu DIAO Pharmaceutical Group CO., LTD.8 studiesSame company
Something wrong?
- Chendu DIAO Nine Hong Pharmaceutical Factory1 study →Subsidiary
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 9 of 9.
- Mass Balance Study of [14C]DA-302168S in Healthy Chinese Adult Male ParticipantsNot yet recruitingNCT07857265Phase 1
- Pharmacokinetics, Safety, and Tolerability of DA-302168S Tablets in Participants With Hepatic Impairment and Normal Hepatic FunctionNot yet recruitingNCT07877038Phase 1
- A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 DiabetesNot yet recruitingNCT07755150Phase 2
- A Study of DA-302168S in Participants With Overweight/ObesityRecruitingNCT07629544Phase 3
- Safety, Tolerability and Pharmacokinetic Characteristics Evaluation on DA414RecruitingNCT06525168Phase 1
Sponsor listed in the registry: Chendu DIAO Nine Hong Pharmaceutical Factory
- A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese SubjectsCompletedNCT06953063Phase 2
- The Food Effect on Pharmacokinetics of DA-302168SCompletedNCT06534346Phase 1
- A Study Evulating DA-302168S Tablets in Overweight/Obese SubjectsCompletedNCT06541730Phase 1
- Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S TabletsCompletedNCT06534320Phase 1